SR Pharma Appoints Dr David Hill As Chief Executive Officer          

London, UK. 19 May 2003SR Pharma plc (LSE: SPA) announces the appointment
today of Dr David Hill as Chief Executive Officer and a member of the Board of
Directors. Dr Hill, who has 20 years of business experience in the
biopharmaceutical industry, will be responsible for building and implementing a
strategy for the Company that will maximise the return on its investments and
shareholder value and take it successfully through the next three to five
years.

Most recently, Dr Hill (aged 52) was CEO of Sedac-Therapeutics, an
immunotherapy product development company based in Lille, France. During his
time at Sedac, Dr Hill managed the transition of the company out of academia
and into a commercial organisation capable of progressing products
independently towards clinical development.

Prior to this, Dr Hill has held senior positions at Iomai Corporation in the
USA, Medeva plc in the UK, and he was responsible for starting a division of
Covance Inc. in the UK.

Commenting on today's appointment, Eric Boyle, SR Pharma's Chairman, said:
"David brings to SR Pharma a wealth of experience in worldwide commercial and
organisation development in the biopharmaceutical industry, particularly in
managing companies through periods of change or transition. His expertise in
developing vaccines, cancer and inflammatory disorder products will be
extremely beneficial to SR Pharma."

David Hill said: "I am very pleased to be joining SR Pharma at this stage in
its development. In my opinion, the company has great potential and it is my
responsibility to define the strategy that maximises the value of that
potential. I am very much looking forward to the challenges ahead."

In addition, the Company advises that there are no matters under paragraph 6F2
(b) to (g) of the Listing Rules to be disclosed in relation to Dr. Hill.

About SR Pharma
SR Pharma plc (www.srpharma.com) was founded in 1992 and develops novel
medicines based on an improved understanding of the role played by the immune
system in combating disease. The company's proprietary technologies are the
source of a number of product developments. SR Pharma is currently evaluating
SRP299 and AVAC(tm) for the treatment of asthma and atopic dermatitis (eczema).
The company is also investigating SRL172 as a vaccine adjuvant in cancer and
infectious diseases. These products enhance the immune responses needed to
combat cancer and infection, while regulating those that mediate allergies.

For further information please contact:
Steeve Lamontagne, SR Pharma plc
Tel: +44 (0) 20 7307 1628
Email: s.lamontagne@srpharma.com



END